Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.
Metro G, Fabi A, Mirri MA, Vidiri A, Pace A, Carosi M, Russillo M, Maschio M, Giannarelli D, Pellegrini D, Pompili A, Cognetti F, Carapella CM. Metro G, et al. Among authors: russillo m. Cancer Chemother Pharmacol. 2010 Jan;65(2):391-7. doi: 10.1007/s00280-009-1155-x. Epub 2009 Oct 22. Cancer Chemother Pharmacol. 2010. PMID: 19847425 Clinical Trial.
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Fabi A, Metro G, Papaldo P, Mottolese M, Melucci E, Carlini P, Sperduti I, Russillo M, Gelibter A, Ferretti G, Tomao S, Milella M, Cognetti F. Fabi A, et al. Among authors: russillo m. Cancer Chemother Pharmacol. 2008 Sep;62(4):717-25. doi: 10.1007/s00280-007-0650-1. Epub 2007 Dec 6. Cancer Chemother Pharmacol. 2008. PMID: 18071704 Clinical Trial.
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.
Fabi A, Metro G, Ferretti G, Giannarelli D, Di Cosimo S, Papaldo P, Mottolese M, Carlini P, Felici A, Russillo M, Cognetti F. Fabi A, et al. Among authors: russillo m. Breast. 2008 Oct;17(5):499-505. doi: 10.1016/j.breast.2008.03.006. Epub 2008 May 1. Breast. 2008. PMID: 18450443 Free article. Review.
Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study.
Fabi A, Ciccarese M, Metro G, Savarese A, Giannarelli D, Nuzzo CM, Russillo M, Sperduti I, Carbone I, Bria E, Cognetti F. Fabi A, et al. Among authors: russillo m. Support Care Cancer. 2008 Dec;16(12):1375-80. doi: 10.1007/s00520-008-0438-9. Epub 2008 May 14. Support Care Cancer. 2008. PMID: 18478278 Clinical Trial.
Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.
Fabi A, Metro G, Vidiri A, Lanzetta G, Carosi M, Telera S, Maschio M, Russillo M, Sperduti I, Carapella CM, Cognetti F, Pace A. Fabi A, et al. Among authors: russillo m. J Neurooncol. 2010 Nov;100(2):209-15. doi: 10.1007/s11060-010-0163-3. Epub 2010 Mar 30. J Neurooncol. 2010. PMID: 20352471 Clinical Trial.
65 results